Reports from other cancer types targeted with FGFR1 inhibitors support the notion that inhibitors do not have equivalent efficiency varying from one tumor type and drug family to another suggesting the FGFR alterations have different biological meanings (32). The gene discussed is FGFR1; the disease is neoplasm.